Sarepta Therapeutics Opens Applications for 8th Annual Route 79 Duchenne Scholarship Program Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine for rare diseases, has officially opened applications…
CHMP Recommends EU Approval of ENHERTU® for HER2 Low/Ultralow Metastatic Breast Cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have achieved a significant milestone with the recommendation for approval…
Seismic Therapeutic Presents Preclinical Data on S-8484 for Allergic Diseases Seismic Therapeutic, Inc., a pioneering machine learning immunology company, has announced the presentation of preclinical data for its novel immunoglobulin…
BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS…
Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases,…
Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations Vertex Pharmaceuticals (Nasdaq: VRTX) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion Predictmedix AI Expands into US Market with Launch of Advanced AI Health Stations Predictmedix AI Inc. (CSE: PMED) (OTC:…
SINOVAC Announces New Board Following Privy Council Judgment and Outlines Next Steps Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, has announced significant developments…
Identiv and Novanta Forge Strategic Partnership to Accelerate Adoption of RFID Solutions in Healthcare OEMs Novanta Inc., a leading global technology supplier serving the medical device and life sciences markets,…
Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing…
IPA and RIBOPRO Forge Strategic Partnership to Revolutionize mRNA-Based Antibody Discovery and Expand Immunotherapy Horizons ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody…
Aurinia Pharmaceuticals Announces Strong Financial Performance for Q4 and Full Year 2024, Provides Corporate Updates Fourth Quarter and Full-Year 2024 Financial Performance Highlights Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading…